Navigation Links
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
Date:11/19/2007

sicians consider starting with combination therapy for most patients with stage 2 hypertension," said Dr. Michael Weber, Professor of Medicine, SUNY Downstate College of Medicine. "In addition, the approval of AVALIDE(R) (irbesartan-hydrochlorothiazide) as a first-line therapy in patients likely to need multiple drugs to achieve their blood pressure goals provides physicians with an FDA-approved therapeutic option in one tablet."

ABOUT AVAPRO(R) (irbesartan) and AVALIDE

In the United States, AVAPRO is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

AVAPRO is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation).

AVALIDE is a fixed-dose combination of the angiotensin II receptor blocker (ARB) AVAPRO and a diuretic (hydrochlorothiazide).

AVALIDE is indicated for the treatment of hypertension.

AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy.

AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks.

IMPORTANT SAFETY INFORMATION

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO or AVALIDE should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

-- Because o
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014   Coqui RadioPharmaceuticals Corp. , a medical ... producer of Molybdenum-99 (Mo-99), is proud to announce it ... to design its Medical Isotope Production Facility (MIPF) in ... parent isotope of Technetium-99, which is used in 80 ... passed legislation making it a national priority to produce ...
(Date:11/21/2014)... 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... announced underwritten public offering of $50,000,000 of shares of ... statement. The offering will consist of 49,751,244 shares of ... per share.  Lexicon has also granted the underwriters a ... of common stock.  All of the shares in the ...
(Date:11/18/2014)... Mass. , Nov. 18, 2014 Respiratory ... of the leading medical device and services providers in ... exclusive partner for Respiratory Motion,s innovative respiratory depression monitor, ... Motion and IMI are working together to connect the ... has a long history of bringing innovative medical devices ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
(Date:11/21/2014)... November 21, 2014 Body Well Therapy, a ... it accepts Spafinder massage gift cards and ... hotel massage in all service areas including throughout Florida and ... to go to the spa at all to redeem your ... of Body Well. "We may not be able to transport ...
(Date:11/21/2014)... Richard Wolfe, co-founder and CEO of ... benefits administration strategies during the Game Changer session ... This Game Changer breakout session enables emerging providers ... solutions and best practices to top HR leaders. ... exchange between health and welfare benefits partners, HR ...
(Date:11/21/2014)... 21, 2014 Big Bud Farms announced ... episode of Innovations with Ed Begley Jr., airing via ... TBA. , Big Bud Farms, growers of legal medical ... and utilization of medical marijuana. , This segment of ... wide variety of products for medicating. Viewers will learn ...
(Date:11/21/2014)... 2014 In summer, when it’s hot ... rarely perspire and rarely feel thirsty. As a result, ... eight glasses of fresh water a day recommended for ... advocate Sharon Kleyne. Winter weather is often more dehydrating ... as important.     , The syndicated Sharon ...
(Date:11/21/2014)... Recently, TideStore.com, a leading online store ... its special offer TideStore Thanksgiving Sales . According ... are now provided with big discounts. The special offer ... enjoy an extra 10% discount with this coupon code: ... and have opportunities to win free gifts. TideStore.com has ...
Breaking Medicine News(10 mins):Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 2Health News:Our Bodies Need Eight Glasses of Water a Day Even in Winter Reports Fresh Water Advocate 3Health News:Thanksgiving Sales from TideStore.com 2
... which men are at increased risk, scientists say , MONDAY, ... identified key gene variants tied to an increased risk of ... step toward understanding which men are at high risk for ... not been any clear genetic risk factors that can account ...
... , RESEARCH TRIANGLE PARK, N.C. , June 1 ... the U.S. Food and Drug Administration has approved Lamictal(R)XR(TM) ... years of age or older with partial onset seizures. Lamictal ... current therapy. , , Lamictal XR reduced the ...
... for oncology procedures. , , ST LOUIS, ... that it has entered into an agreement with ... worldwide license to intellectual property from Medtronic related ... Medtronic has developed significant intellectual property in the ...
... shows that gay and lesbian couples are forming long-term, ... to marry. However, couples surveyed for the study overwhelmingly ... order to secure legal rights such as retirement ... is both more and less important to gay and ...
... Status in 2018, According to a New Report from ... Decision Resources, one of the world,s leading research ... that Amgen,s novel agent denosumab and Eli Lilly,s parathyroid ... percent annual growth in the osteoporosis drug market from ...
... --Company Focuses on Rebuilding Revenue Base While Stabilizing ... , VANCOUVER, June 1 /PRNewswire-FirstCall/ - Vancouver, BC, Canada - ... three months ended March 31, 2009. , "The first quarter ... last year to refocus Neovasc on our most promising growth ...
Cached Medicine News:Health News:Researchers Spot Genes Linked to Testicular Cancer 2Health News:FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy 2Health News:FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy 3Health News:FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy 4Health News:FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy 5Health News:FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy 6Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Study shows gay couples want legal rights, regardless of marriage 2Health News:Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 2Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 3Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 4Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 5Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 6Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 7Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 8Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 9Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 10Health News:Neovasc Inc. Reports First Quarter 2009 Financial Results 11
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: